Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere, the ...

This was the stock's second consecutive day of gains.

01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...

Looking ahead, once-yearly HIV prevention injections could be on the horizon, Gilead Sciences executives said at a December ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

Gilead teams up with Terray for AI-powered drug discovery, leveraging Terray’s tNova platform to accelerate the development ...

Gilead Sciences (NASDAQ:GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop ...

Assembly Biosciences (ASMB) announced an equity investment of $20.1M by Gilead Sciences (GILD) to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance the ...

(RTTNews) - Assembly Biosciences, Inc. (ASMB), Thursday announced that the company has received a total of $30.1 million from Gilead Sciences, Inc. Of the total amount, $20.1 million is an equity ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.